Background: Sublobar resection for non-small cell lung cancer (NSCLC) remains controversial owing to concern about local recurrence and long-term survival outcomes. We sought to determine the efficacy of wedge resection as an oncological procedure.
S
urgical resection in the form of lobectomy or pneumonectomy remains the standard of care for stage I and II non-small cell lung carcinoma (NSCLC) despite advances in chemotherapy and radiation therapy. 1 Owing to the primary causative relationship of smoking to NSCLC and associated cardiopulmonary comorbidities, many patients are deemed medically unfit to withstand full lobectomy. The best management for these patients remains controversial; many modalities are available, necessitating further investigation on this topic. 2 These modalities include sublobar resection (wedge resection or anatomic segmental resection), observation, conventional fractionated or stereotactic body radiotherapy (SBRT) and radiofrequency ablation. [3] [4] [5] [6] [7] Many surgeons still prefer sublobar resections over SBRT and ablative therapies despite successful local control rates having been reported with SBRT, particularly by Timmerman and colleagues. 8 Controversy remains as to whether sublobar resections are adequate oncologic procedures for patients with severely impaired pulmonary function who could not withstand lobectomy. 2, 9 This relates to concern that despite preservation of pulmonary function, tumour resection margins may be compromised with inadequate nodal sampling, possibly understaging the primary tumour. 10 This could lead to increased rates of local and systemic recurrence and decrease disease-free and overall survival. 11 All but 1 previous study examining sublobar resections for NSCLC have been retrospective in nature, many revealing conflicting results. The prospective trial by Ginsberg and Rubinstein 13 concluded that lobectomy was preferred over limited resections owing to decreased rates of local recurrence. This landmark study did not account for tumour diameter or location of the early-stage lesions. It has since been postulated that sublobar resection is an adequate oncologic surgery for peripheral lesions less than 2 cm in diameter, especially in the setting of a second primary lung cancer, adenocarcinoma in situ, or ground-glass opacities. 29, [33] [34] [35] [36] [37] [38] [39] [40] All previous studies have used the sixth edition American Joint Committee in Cancer (AJCC) tumour-node-metastasis (TNM) classification and focused on comparing outcomes of segmental resection to lobectomy. 41 Only 1 previous nonCanadian study has focused on comparing outcomes of wedge resection to lobectomy; however, this study also used the sixth edition AJCC TNM classification. 31 The purpose of the present study was to determine whether there is a significant difference in tumour recurrence and survival in patients who undergo wedge resections versus lobectomy for NSCLC based on the seventh edition AJCC TNM classification and thus to determine whether wedge resection is an adequate oncologic procedure to offer patients.
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METHODS
This was a retrospective analysis of all patients who underwent lung resection for NSCLC at the Cancer Centre of Southeastern Ontario for the fiscal years 1998 to 2009. All patients were pathologically staged according to the seventh edition AJCC TNM classification. Lobectomy or pneumonectomy was the standard of care performed for patients with adequate pulmonary function. Sublobar resection was reserved for patients with cardiopulmonary comorbidities precluding lobectomy. We compared the outcomes of patients who underwent either of these 2 procedures during the study period. This study received research ethics board approval from the research ethics board at Queen's University in Kingston, Ont.
We collected data on basic demographics (age, sex), patient comorbidities (coronary artery disease, chronic obstructive pulmonary disease [COPD], diabetes), operative details (type of surgery, anatomic location), tumour pathological characteristics (margin status, histology, differentiation, presence of lymphatic or vascular invasion), disease recurrence, mortality (including cause of death) and morbidity (prolonged air leak, cardiac arrhythmia).
Primary outcomes included incidence of local-regional and distant recurrence, disease-free survival and overall survival. Disease recurrence was defined as the incidence of recurrent carcinoma (local-regional or distant), diseasefree survival was the time from surgery to diagnosis of recurrent carcinoma, and overall survival was the time from surgery to death or last known follow-up. Secondary outcomes included length of hospital stay and postoperative complications, including prolonged air leak and cardiac arrhythmia. Prolonged air leak was defined as an air leak from the chest tube lasting more than 5 days. Cardiac arrhythmia was defined as an acute change in the patients' electrocardiogram to display atrial fibrillation, atrial flutter or multifocal atrial tachycardia (MAT).
Statistical analysis
Data were entered in Excel and imported into PASW Statistics (SPSS Inc.) for analysis. Following a descriptive analysis (means, standard deviations and medians for continuous data, frequencies for categorical data), continuous data were plotted to assess the normality of the distribution. We used χ 2 tests (Pearson or Fisher exact, as appropriate) to compare the lobectomy and wedge groups on categorical data, such as sex, comorbidities and complications. We performed independent samples t tests to compare the groups on age and tumour diameter and the nonparametric Mann-Whitney U test to compare the groups on length of stay in hospital. We used Kaplan-Meier analysis to compare the groups on time to recurrence. We also performed subset analyses for cancer stage, tumour stage and smoking status. neoadjuvant and adjuvant chemoradiotherapy ( Table 1) . The mean time to recurrence was 22 months in patients who underwent lobectomy and 21 months in those who underwent wedge resection; mean follow-up after surgery was 39 months and 37 months, respectively, and mean follow-up after recurrence was 14 months and 13 months, respectively. The mean age of patients was 64.7 (range 28-82) years. Most patients were smokers (388, 91.7%). Patient who underwent wedge resections were more likely to have COPD by spirometry than those who underwent lobectomy (46.5% v. 28.9%, p = 0.004). The groups were balanced with respect to the presence of other significant comorbidities, such as coronary artery disease, diabetes and substance abuse ( Table 1) .
With respect to pathological outcomes, distribution of tumour histology, margin status, differentiation and presence of lymphatic or vascular invasion were also balanced between cohorts (Table 2) . Patients who underwent wedge resection were more likely than those who underwent lobectomy to have a smaller tumour diameter (p < 0.001) and to have a tumour less than 2 cm in size (p = 0.009). They also tended to have stage IA disease (p = 0.021). Table 3 shows the disease-free survival and overall survival, by tumour stage and by cancer stage, for patients in the lobectomy and wedge resection groups. Between-group differences in disease-free survival existed for both tumour stage and cancer stage (p = 0.043 and p = 0.008, respectively), but between-group differences in overall survival fell short of significance (p = 0.08 and p = 0.09, respectively).
In comparing surgical outcomes between the 2 cohorts there was a trend that patients who underwent lobectomy had a longer stay in hospital than those who underwent wedge resection (7.7 d v. 6.8 d, p = 0.09), although the median values (6 d) were the same. There was no significant difference in 30-day mortality (4 deaths in the lobectomy group v. 2 in the wedge resection group). There were higher rates of prolonged air leak in the lobectomy group than the wedge resection group (12.5% v. 7%, p = 0.19), but the sample was too small to reach statistical significance. Similarly there were higher rates of atrial fibrillation, flutter and MAT in the lobectomy group than the wedge resection group (6% v. 1.4%); however, this difference did not attain statistical significance.
For disease-free survival there was no significant difference between wedge resection and lobectomy (p = 0.59).
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DISCUSSION
This Canadian study carried out at a tertiary care university hospital is unique in that it predominantly compares wedge resection (as opposed to segmental resection) with lobectomy for the surgical management of NSCLC. In addition, the groups were stratified by tumour size and based on the seventh edition AJCC TNM classification. We observed similar rates of disease-free and overall survival for patients with early-stage NSCLC undergoing lobectomy and wedge resection.
Limitations
The limitations of this study arise primarily from its retrospective nature and 11-year duration. Some patient data on preoperative cardiopulmonary assessment (pulmonary function and echocardiography test results) were simply not available. However, given our institution's adherence to widely accepted guidelines (Cancer Care Ontario, American College of Chest Physicians and National Comprehensive Cancer Network guidelines) for the conduct of preoperative assessment and pulmonary resection, along with the demographic and comorbidity data provided, readers are still able to extrapolate the applicability of these results to their own patients. In addition, during the 11-year course of this study, practice standards regarding lymph node assessment and adjuvant therapy protocols changed. We strongly feel that this would not have affected the results substantially, given that only those patients with the smallest tumours (≤ 2 cm) who underwent wedge resection had similar survival to those who underwent lobectomy. These patients would have been unlikely to receive chemotherapy, even with the new standard of care.
It is important to recognize that patients with compromised pulmonary reserve may be more likely to die sooner than those without compromised pulmonary reserve of causes other than lung cancer recurrence, thus potentially decreasing overall survival and artificially inflating the disease-free survival in this group. Furthermore, patients who underwent wedge resection were more likely to have documented COPD than those who underwent lobectomy. In addition, the wedge resection cohort was selected to have smaller (< 2 cm), earlier staged tumours (stage IA or IB) than the lobectomy cohort. For tumours smaller than 2 cm in size, patients who underwent lobectomy had a significantly increased length of hospital stay. This may be due to the complication of prolonged air leak, for which we observed a trend toward higher rates.
CONCLUSION
These data demonstrate that in properly selected pa tients wedge resection for NSCLC has the potential to be an adequate oncologic procedure. Specifically, the eligible patient groups include those with small tumours (< 2 cm in diameter) and seventh edition AJCC stage IA or IB disease. This is supported by similar rates of disease-free and overall survival observed in these cohorts. Furthermore, we await the results of the on going National Cancer Institute of Canada Clinical Trials Group phase III randomized trial of lobectomy versus sublobar resection for tumours smaller than 2 cm in patients with peripheral NSCLC (BRC.5 CALGB 140503) to learn whether similar survival outcomes to those in our retrospective analysis can be observed in the prospective setting.
